GLP-1 Agonists and Endoscopy: GI Specialists Issue Statement
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
Diagnosis & Disease Information
Brenzavvy Now Available for Adults With Type 2 Diabetes
Brenzavvy is an oral sodium-glucose cotransporter 2 inhibitor.
Empagliflozin Approved for Pediatric Patients With Type 2 Diabetes
The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial.
FDA Concerned Over Compounded Semaglutide Following Reports of Adverse Events
Semaglutide, a GLP-1 receptor agonist, is currently approved under 3 brand names: Ozempic, Rybelsus, and Wegovy.
Substantial Weight Loss Observed With Tirzepatide for Type 2 Diabetes
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Greater HbA1c, Weight Loss Reductions Seen With Oral Semaglutide at Higher Doses
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Brenzavvy Approved for Adults With Type 2 Diabetes
The approval was based on data from a clinical program that included 23 clinical trials enrolling more than 5000 adults with type 2 diabetes mellitus.
Subpotent Oral Solution Prompts Recall of Hypothyroidism Treatment
The use of recalled products may lead to signs and symptoms of hypothyroidism.
Diabetes Treatment Adlyxin Will No Longer Be Available in the US
A recent posting on the FDA’s Drug Shortages tracker indicates that the product has been discontinued.
Additional Dosing Options of Tirosint-SOL Now Available
Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.
- Loading...
Loading...
Next post in News
Loading... 
Loading...